Actimed Therapeutics, a London, UK-based clinical stage specialty pharmaceutical company, raised £5M in Series A funding.
The round saw participation from existing investors, including India-based pharmaceutical company, Mankind Pharma (market cap ~US$8.3bn), together with a number of new non-institutional investors.
The company intends to use the funds to support the development of its pipeline, including S-pindolol benzoate, with preparations under way for a Phase 2b/3 programme (the “IMPACT” programme) targeted at the treatment of cancer cachexia in non-small cell lung cancer and colorectal cancer.
Founded in 2017 by Stefan Anker and Andrew Coats, and led by CEO Robin Bhattacherjee, Actimed Therapeutics is a clinical stage specialty pharmaceutical company focused on the treatment of muscle wasting disorders to transform the care of an underserved and vulnerable patient population. The lead area of focus for the company is specifically in cachexia that is a wasting disease that is associated with cancer and other serious chronic illnesses and with significant morbidity and mortality. A significant number of cancer patients suffer from cachexia and it is estimated that cachexia is responsible for up to 20% of all cancer deaths.
FinSMEs
26/06/2023